Project Grant R01HL175366
Award Date
7/15/25
Completion Date
4/30/29
Dollars Obligated
$736K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of reduced hypusination of the translation factor EIF5A in the development of heart failure with preserved ejection fraction (HFpEF). The $126,387 award to The Johns Hopkins University, granted on June 15, 2025, aims to study how depressed EIF5A hypusination impairs the translation of ubiquitin precursors and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $121,773 to the University of Arizona to investigate the role of the serum/glucocorticoid regulated kinase 1 (SGK1) in driving pathological cardiac hypertrophy. The research aims to determine if SGK1 is required for the development of cardiac hypertrophy and if impairing its degradation through the endoplasmic reticulum-associated degradation (ERAD)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of the serine-threonine kinase, serum glucocorticoid kinase 1 (SGK1), in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The $732,779 award to the University of Utah aims to: (1) determine the role of cardiac-specific SGK1 in regulating heart function, metabolism, and inter-organ...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $654,530 to the University of Utah to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (cMet HFPEF). The 4-year project aims to determine how cardiac-specific SGK1 signaling, particularly through its phosphorylation of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $173,352 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) to conduct research on molecular characterization of frailty and functional limitations in heart failure with preserved ejection fraction (HFpEF). The key products and services to be delivered under this 5-year award, which began on Jul 15, 2025, include: Measuring associations between the human proteome and...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...